Prostate cancer screening after 40

Prostate cancer screening in Europe 2026: PSA, MRI and when to start testing

Prostate cancer screening in Europe looks very different in 2026. The focus is shifting from one-size-fits-all checks to a more personalised, risk-adapted approach.

In practice, this means:

• starting with a PSA blood test;

• evaluating PSA trends rather than a single result;

• using MRI before biopsy when clinically appropriate.

PSA is a protein measured in blood, and levels may increase for non-cancerous reasons such as infections, cycling or benign prostate enlargement.

Men in their forties often ask the same questions:

• When should I start screening?

• How often should I repeat PSA testing?

• What happens if PSA rises slightly?

This guide explains:

• who is considered high-risk;

• how baseline PSA affects screening intervals;

• when an mpMRI may help avoid unnecessary biopsy;

• which questions to ask your doctor.

If you prefer to discuss prostate screening remotely, you can speak with a GP or urologist through Oladoctor.

This content is informational only and does not replace medical advice. If you have symptoms or concerns, consult a qualified clinician. In an emergency, contact your local emergency number.

What changed between 2022 and 2026?

Europe has gradually moved from opportunistic PSA testing toward structured, risk-adapted screening pathways.

In December 2022, the EU Council recommended that Member States evaluate organised programmes using:

• PSA as the first screening step;

• MRI before biopsy when results appear suspicious.

By 2026, many European countries are already adapting their national pathways accordingly.

The EAU guidelines now emphasise:

• individual risk assessment;

• baseline PSA;

• shared decision-making;

• MRI as a gatekeeper before biopsy.

In practical terms, biopsy is no longer automatically the first step after a raised PSA.

Countries such as the UK have also refined their diagnostic pathways. NICE guidance updated in 2026 supports MRI-first approaches and recommends repeat PSA testing when suspicion remains low.

Studies such as PROBASE additionally support longer screening intervals in men with very low baseline PSA values, helping reduce unnecessary testing.

Who should consider PSA testing after 40?

Most men can begin discussing PSA screening between their mid-40s and early 50s.

However, some groups are considered higher risk and may benefit from earlier evaluation.

High-risk groups include:

• men with a strong family history of prostate cancer;

• BRCA2 mutation carriers;

• men of Black ancestry;

• men with multiple relatives affected by prostate or related cancers.

For these groups, many experts recommend beginning screening discussions around age 40–45.

Family history and ancestry matter because prostate cancer may develop earlier and progress more aggressively in higher-risk populations.

Two practical principles guide modern European screening:

Your doctor on Oladoctor can help translate this into a realistic long-term screening schedule.

Understanding the PSA test

The PSA test starts a conversation. It does not diagnose cancer on its own.

PSA levels may increase because of:

• infections;

• benign prostate enlargement;

• recent ejaculation;

• cycling;

• urological procedures.

Modern European guidance prefers a risk-adapted approach instead of automatic yearly testing.

How often should PSA be repeated?

The interval depends on:

• baseline PSA;

• age;

• family history;

• MRI findings;

• overall health status.

Typical examples

Large European studies suggest that men with PSA below 1.5 ng/mL may safely wait several years before retesting.

Doctors also evaluate PSA density, calculated as PSA divided by prostate volume.

A commonly used threshold is approximately:

0.15

Higher PSA density may indicate increased risk.

How to prepare before a PSA test

To reduce false-positive results:

• avoid ejaculation for 48 hours;

• avoid intense cycling for 48 hours;

• do not test during a urinary infection;

• inform your doctor about recent urological procedures.

Why MRI before biopsy matters

Modern European pathways increasingly recommend multiparametric MRI (mpMRI) before biopsy.

This approach helps:

• identify clinically significant cancers;

• reduce unnecessary biopsies;

• minimise overdiagnosis.

MRI findings are classified using the PI-RADS scale:

Typical MRI pathway

This MRI-first strategy is now considered safer and more precise than immediate biopsy-first approaches.

New screening tools in 2026

Genetic saliva testing (PRS)

Polygenic risk score (PRS) saliva testing became a major topic in 2026.

Studies such as BARCODE1 suggest PRS may help identify men at higher risk of clinically significant prostate cancer.

However:

• PRS is not yet a stand-alone screening tool;

• guidelines are still evolving;

• genetic screening currently complements rather than replaces PSA.

Additional risk tools

Other tools increasingly used in Europe include:

• Stockholm3 (STHLM3);

• ERSPC risk calculators;

• PHI biomarkers;

• 4Kscore panels.

These may help reduce unnecessary biopsies in borderline cases.

Home PSA kits vs clinical testing

Home PSA kits may seem convenient, but they have important limitations.

Finger-prick tests without medical interpretation can:

• create unnecessary anxiety;

• miss clinical context;

• lead to misinterpretation.

Clinical testing is generally safer because:

• samples are processed in accredited laboratories;

• doctors interpret results alongside symptoms and risk factors;

• proper follow-up can be organised immediately.

Safer testing pathway

If you want a structured plan, a GP or urologist through Oladoctor can help coordinate testing and interpretation remotely.

Questions to ask your doctor

Before your appointment, consider discussing:

• Am I considered high-risk?

• Is baseline PSA appropriate for me now?

• What screening interval would you recommend?

• Which temporary factors may affect PSA?

• When would MRI become necessary?

• How is PSA density interpreted?

• Would genetic counselling or BRCA testing make sense?

• Could any medications affect PSA interpretation?

Saving these questions beforehand can make consultations more focused and practical.

When should prostate cancer screening stop?

Screening decisions later in life should balance:

• potential benefits;

• overdiagnosis risks;

• overall health status;

• life expectancy.

European recommendations increasingly suggest reducing or stopping routine screening after approximately age 70, although decisions remain individualised.

Important considerations

Shared decision-making remains essential.